medigraphic.com

2011, Number 25

<< Back Next >>

Hipoc Rev Med 2011; 6 (25)

Beta-bloqueadores en Insuficiencia Cardiaca Sistólica

Esparragoza-Fox C, Padilla-Ibarra J, Esparragoza-Romano JE

Language: Spanish
References: 35
Page: 6-13
PDF size: 122.52 Kb.


ABSTRACT

Knowledge of the mechanisms of action of beta blockers in the sympathetic system has led to the controversial use of these in heart failure. In spite of their antagonistic effects on chronotropic and inotropic functions of the heart, they are now part of the treatment strategies endorsed by the FDA for heart failure. With the use of beta blockers, a decrease has been observed in pro-inflammatory agents as well as an inhibition of the vasoconstrictor neurohormonal system, the sympathetic system, in response to low output; if these factors are not controlled, heart failure can be perpetuated.
In recent years many clinical studies have been conducted mainly with the use of metoprolol, carvedilol and bisoprolol, with favorable results; increasing survival and decreasing the symptoms, number of hospitalizations and mortality in patients with heart failure. Our objective was to analyze the different studies on the use of beta blockers in heart failure.


REFERENCES

  1. L. Mann D. “Pathophisiology of heart failure”. Libby: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 8th ed. Chapter 22 541-542.

  2. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819.

  3. Floras JS: Sympathetic activation in human heart failure: Diverse mechanisms, therapeutic opportunities. Acta Physiol Scand 2003; 177:391.

  4. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982; 307:205.

  5. RJ Hughes, LC Mahan and PA Insel Certain beta-blockers can decrease beta-adrenergic receptor number: Downregulation of receptor number by alprenolol and propranolol in cultured lymphoma and muscle cellsCirc. Res. 1988;63;279-285

  6. Yoshikawa T, Handa S, Anzai T, et al. Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure. Am Heart J 1996; 131:329.

  7. Murray DR, Prabhu SD, Chandrasekar B. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000; 101:2338.

  8. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000; 101:2103.

  9. Inna Gyorke,* Nichole Hester et al.The Role of Calsequestrin, Triadin, and Junctin in Conferring Cardiac Ryanodine Receptor Responsiveness to Luminal Calcium Biophysical Journal Volume 86 April 2004 2121-2128

  10. Engelhardt Stefan, Boknik Peter “Early impairment of calcium handling and altered expression of junctin in hearts of mice overexpressing the b1-adrenergic receptor1” The FASEB Journal Vol. 15 December 2001 2121-2127.

  11. Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002; 346:1357.

  12. En Vargas J, Férez SM, Leiva JL et al. Tratado de Cardiología. Sociedad Mexicana de Cardiología. 1a edición; Intersistemas, S.A. de C.V. 2006

  13. Marco Metra, Savina Nodari,et al. “Beta Blockers in Heart Failure: Issues in the Management of Individual Patients” Cattedra di Cardiologia, Università di Brescia Heart Failure Reviews 1999;4:65–77.

  14. Marco Metra, Savina Nodari “Beta- Blockers in Heart Failure: Are PharmacologicalDifferences Clinically Important?” Cattedra di Cardiologia, Universit `a di Brescia, Italy;Deptartment of Cardiology, Ospedale di Cattinara, Trieste, Italy; 3National Heart and Lung Institute, Imperial CollegeLondon, UK Heart Failure Reviews, 9, 2004;123:130,

  15. Andréia Biolo, MD, MSc, Nadine Clausell, MD, PhD, Kátia G. Santos, ScD et.al. “Impact of _1-Adrenergic Receptor Polymorphisms on Susceptibility to Heart Failure, Arrhythmogenesis, Prognosis, and Response to Beta-Blocker Therapy” J Cardiol 2008;102:726 –732.

  16. Emil Thattassery, MD and Mihai Gheorghiade, MD Beta Blocker Therapy After Acute Myocardial Infarction in Patients with Heart Failure and Systolic DysfunctionHeart Failure Reviews, 9, 107–113, 2004.

  17. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001; 134:550.

  18. En V Fuster et al., eds., diagnosis and management of heart failure. Chapter 26 Hurst's the Heart, 12th Ed. New York: McGraw-Hill.

  19. Heart failure in patients with left ventricular systolic dysfunction. J Card Fail 2006; 12:e38.

  20. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.

  21. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.

  22. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342:1441.

  23. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001.

  24. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283:1295.

  25. RESOLVD Investigators “Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy.” The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study (RESOLVD) Circulation 2000;101:378-84.

  26. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996; 94:2793.

  27. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996; 94:2800.

  28. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improve- ments in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996; 94:2807.

  29. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349.

  30. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106:2194.

  31. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651.

  32. Lechat P, Escolano S, Golmard JL, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 1997; 96:2197.

  33. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9.

  34. Gottlieb SS, Fisher ML, Kjekshus J, et al. Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation 2002; 105:1182.

  35. Añorve Gallardo A, Sanchez Reyes Elvira “Tratamiento farmacológico de la insuficiencia cardíaca” Servicio de Cardiología adultos B, del Instituto Nacional de Cardiología "Ignacio Chávez". Revista Mexicana de Enfermería Cardiológica 2001;9 (1-4): 31-38.




2020     |     www.medigraphic.com